康柏西普和雷株单抗治疗湿性年龄相关性黄斑变性的成本效益比较

发布时间：2018-01-08 11:26

  本文关键词：康柏西普和雷株单抗治疗湿性年龄相关性黄斑变性的成本效益比较　出处：《中国卫生标准管理》2016年20期 　论文类型：期刊论文

  更多相关文章： 雷株单抗 康柏西普 黄斑变性

【摘要】：目的比较康柏西普和雷株单抗治疗湿性年龄相关性黄斑变性的成本和效益。方法回顾性分析我科用雷株单抗(雷株单抗组)和康柏西普(康柏西普组)治疗湿性年龄相关性黄斑变性的临床效果和费用差异。结果两组术前和术后视力差异均无统计学意义(P0.05);雷株单抗组人均医疗费用高于康柏西普组(P0.01)。结论康柏西普和雷株单抗治疗湿性年龄相关性黄斑变性具有同等的效果,应用康柏西普治疗的费用低于雷株单抗。
[Abstract]:Objective to compare the Xipu Compaq and ray mAb treatment of wet age-related macular degeneration and cost benefit. Methods a retrospective analysis using monoclonal antibody (McAb Lei Lei group) and Compaq SEPR (Compaq SEPR group) the clinical effect and the cost difference between the treatment of wet age-related macular degeneration. Results there were no significant differences the vision of two groups before and after operation (P0.05); Lei mAbs group the average medical expense is higher than that of the Compaq etanercept group (P0.01). Conclusion Xipu Compaq and ray mAb treatment of wet age-related macular degeneration has the same effect, the cost of treatment is lower than the application of Compaq SEPR Lei mAbs.

【作者单位】： 陕西省西安中学;西安市第一医院眼科;
【分类号】：R774.5
【正文快照】： 年龄相关性黄斑变性(ARMD)是年龄在50岁以上人群中不可逆性中心视功能损害的首位致盲性眼病,其中湿性ARMD对视功能的损害高于干性ARMD[1]。玻璃体腔注射抗血管内皮细胞生长因子(VEGF)药物是治疗湿性ARMD的有效方法,目前临床上应用的抗VEGF药物主要有阿瓦斯丁(Avastin)、雷珠单，

本文编号：1396921